Literature DB >> 1569968

Variable transcriptional activity and ligand binding of mutant beta 1 3,5,3'-triiodothyronine receptors from four families with generalized resistance to thyroid hormone.

C A Meier1, B M Dickstein, K Ashizawa, J H McClaskey, P Muchmore, S C Ransom, J B Menke, E H Hao, S J Usala, B B Bercu.   

Abstract

Mutations in the gene encoding the human beta 1 T3 receptor (hTR beta 1) have been associated with generalized resistance to thyroid hormone (GRTH). We measured the T3-binding affinity and transcriptional regulatory capacity of the mutant hTR beta 1 from four unrelated kindreds with GRTH. These mutations are contained in different functional regions of the ligand-binding domain. The T3 affinity of the mutant receptors correlated well with the degree of impairment of their trans-activating function in a transient cotransfection system in HeLa cells; two mutant receptors with undetectable ligand affinity showed no transcriptional activity, whereas the two other mutants characterized by a 2- and 5-fold reduction in T3 affinity required 5- and 15-fold higher T3 concentrations for half-maximal activity in the cotransfection assay, respectively. All of the mutant hTR beta 1s were able to inhibit the function of transfected normal hTR beta 1 and endogenous retinoic acid receptor in activating a palindromic positive T3 response element (TRE). In the partially functional mutants this dominant negative effect could be completely reversed by increased T3 concentrations. The dominant negative potency did not depend on the type of TRE used; mutant hTR beta 1s were able to inhibit normal receptor function to the same degree on a dimer-permissive palindromic TRE as on a nondimer-permissive inverted repeat of two identical half-sites separated by five spacer bases. However, the dominant negative potency was dependent on the absolute amount of receptor expression vector transfected. The expression of normal and mutant hTR beta 1 was assessed by immunocytochemistry. The hTR beta 1 protein levels in HeLa cells paralleled the amount of transfected expression vector. Moreover, all the mutant receptors were properly expressed in the nuclei of the transfected cells. These data suggest that different mutations in the ligand-binding domain of the human hTR beta 1 result in a variable degree of functional impairment, which may partially explain the phenotypic differences between kindreds with GRTH. Our findings suggest that competition for binding to the TRE and possibly the binding of limiting accessory factors may be more important in mediating the dominant negative effect than the formation of normal/mutant T3 receptor dimers.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569968     DOI: 10.1210/mend.6.2.1569968

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  35 in total

1.  Impaired adipogenesis caused by a mutated thyroid hormone alpha1 receptor.

Authors:  Hao Ying; Osamu Araki; Fumihiko Furuya; Yasuhito Kato; Sheue-Yann Cheng
Journal:  Mol Cell Biol       Date:  2007-01-12       Impact factor: 4.272

2.  Transgenic mice bearing a human mutant thyroid hormone beta 1 receptor manifest thyroid function anomalies, weight reduction, and hyperactivity.

Authors:  R Wong; V V Vasilyev; Y T Ting; D I Kutler; M C Willingham; B D Weintraub; S Cheng
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

3.  Hyperactivity and learning deficits in transgenic mice bearing a human mutant thyroid hormone beta1 receptor gene.

Authors:  M P McDonald; R Wong; G Goldstein; B Weintraub; S Y Cheng; J N Crawley
Journal:  Learn Mem       Date:  1998 Sep-Oct       Impact factor: 2.460

4.  A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone.

Authors:  T N Collingwood; R Wagner; C H Matthews; R J Clifton-Bligh; M Gurnell; O Rajanayagam; M Agostini; R J Fletterick; P Beck-Peccoz; W Reinhardt; G Binder; M B Ranke; A Hermus; R D Hesch; J Lazarus; P Newrick; V Parfitt; P Raggatt; F de Zegher; V K Chatterjee
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

5.  PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.

Authors:  C J Guigon; L Zhao; M C Willingham; S-Y Cheng
Journal:  Oncogene       Date:  2008-11-10       Impact factor: 9.867

6.  Thyroid hormone resistance from newborns to adults: a Spanish experience.

Authors:  A Vela; G Pérez-Nanclares; I Ríos; I Rica; N Portillo; L Castaño
Journal:  J Endocrinol Invest       Date:  2019-02-01       Impact factor: 4.256

7.  Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency.

Authors:  C A Meier; C Parkison; A Chen; K Ashizawa; S C Meier-Heusler; P Muchmore; S Y Cheng; B D Weintraub
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

8.  Kindred S thyroid hormone receptor is an active and constitutive silencer and a repressor for thyroid hormone and retinoic acid responses.

Authors:  A Baniahmad; S Y Tsai; B W O'Malley; M J Tsai
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

9.  Human small cell lung cancer cell lines expressing the proopiomelanocortin gene have aberrant glucocorticoid receptor function.

Authors:  D W Ray; A C Littlewood; A J Clark; J R Davis; A White
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

10.  Cell type-dependent modulation of the dominant negative action of human mutant thyroid hormone beta 1 receptors.

Authors:  R Wong; X G Zhu; M A Pineda; S Y Cheng; B D Weintraub
Journal:  Mol Med       Date:  1995-03       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.